{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:59Z","timestamp":1792813259039,"version":"4.5.0"},"reference-count":51,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Janus kinase inhibitors are the cornerstone of treatment for myelofibrosis, but have limited disease\u2010modifying activity. Combinations of ruxolitinib with pelabresib, navitoclax, or selinexor improve spleen responses, although benefits for symptoms and anemia are less consistent, and toxicity may increase. Such approaches may optimize splenomegaly before transplantation. Emerging\n                    <jats:italic>CALR<\/jats:italic>\n                    \u2010directed therapies, particularly INCA033989, offer potential for selective suppression of the malignant clone while improving spleen, anemia, and symptom outcomes. Anemia\u2010directed agents targeting TGF\u2010\u03b2\/BMP\u2010SMAD signaling, including luspatercept, elritercept, and selcodebart, may reduce transfusion burden. Future strategies should align treatment with therapeutic intent and prioritize transplantation, molecular response, progression\u2010free survival, and overall survival endpoints.\n                  <\/jats:p>","DOI":"10.1002\/ajh.70543","type":"journal-article","created":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:58:07Z","timestamp":1792810687000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Drugs in Myelofibrosis: Incremental Progress in Symptom Management Without Disease Modification"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliera Universitaria Careggi, University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms Azienda Ospedaliera Universitaria Careggi, University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1590"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.4418"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(17)30237\u20105"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201002\u2010785923"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27163"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282612"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115840"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(24)00067\u2010X"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26857"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010025\u201003572\u20103"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032360"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco\u201026\u201001080"},{"issue":"1","key":"e_1_2_16_17_1","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2025-910","article-title":"Durable Efficacy and Long\u2010Term Safety With Pelabresib Plus Ruxolitinib in JAK Inhibitor\u2013Naive Myelofibrosis: 96\u2010Week Results From the Phase III MANIFEST\u20102 Study","volume":"146","author":"Rampal R. M. J.","year":"2025","journal-title":"Blood"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.188"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010023\u201001968\u20108"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27292"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27570"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201009\u2010671172"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201011\u2010681932"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.Cd\u201015\u20101434"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2026.100193"},{"issue":"1","key":"e_1_2_16_28_1","article-title":"Mutant Calreticulin\u2013Specific Monoclonal Antibody, INCA033989, Is Well Tolerated and Achieves Robust Spleen, Anemia, and Molecular Responses in Patients (Pts) With Myelofibrosis (MF)","volume":"10","author":"Harrison C. G. V.","year":"2026","journal-title":"HemaSphere"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027897"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27659"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012939"},{"issue":"1","key":"e_1_2_16_32_1","article-title":"Update From the Phase 2 Restore Trial of ELRITERCEPT in Patients With Myelofibrosis (MF) Receiving RUXOLITINIB","volume":"10","author":"Rinaldi C. R. D.","year":"2026","journal-title":"HemaSphere"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.6501"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3512"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010152814"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014172"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9867"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100028\u2010x"},{"issue":"1","key":"e_1_2_16_39_1","article-title":"Efficacy and Safety of LUSPATERCEPT in Patients With Myelofibrosis on Janus Kinase Inhibitors Who Require Red Blood Cell Transfusions: Primary Analysis of the Phase 3 Independence Trial","volume":"10","author":"Passamonti F. K. J.","year":"2026","journal-title":"HemaSphere"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.06.006"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028645"},{"issue":"1","key":"e_1_2_16_42_1","article-title":"Results of AJX\u2010101, A Phase 1 Clinical Trial of the Type II JAK2 Inhibitor AJ1\u201011095, in Patients With Myelofibrosis Who Have Been Failed by A Type I JAK2 Inhibitor","volume":"10","author":"Mascarenhas J. B. U.","year":"2026","journal-title":"HemaSphere"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.Mct\u201014\u20100710"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.313"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010201642"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2026.2638989"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02864"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20102052"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS6588"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2026.06.008"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2422835"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025802"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70543","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70543","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70543","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:58:09Z","timestamp":1792810689000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":51,"alternative-id":["10.1002\/ajh.70543"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70543","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"2026-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajh.70543"}}